When to Discontinue Methimazole in Graves' Disease
Discontinue methimazole after 12-18 months of treatment in adults (or 24-36 months in children) if TSH receptor antibodies (TSH-R-Ab) have normalized, as this timing balances treatment efficacy with relapse risk, though extending therapy to 60-120 months dramatically reduces recurrence rates from 53-56% to 15-17%.
Standard Discontinuation Timeline
Adults with Graves' Disease
- Conventional approach: Stop after 12-18 months of euthyroid control with methimazole, checking TSH-R-Ab levels before discontinuation 1
- If TSH-R-Ab remains persistently elevated at 12-18 months, either continue methimazole for another 12 months and recheck, or proceed to definitive therapy (radioactive iodine or thyroidectomy) 1
- Monitor free T4 or free thyroxine index (FTI) every 2-4 weeks during treatment to maintain levels in the high-normal range using the lowest possible dose 2
Pediatric Patients
- Recommended duration: 24-36 months before considering discontinuation in children with Graves' disease 1
- Longer treatment courses (96-120 months) in juveniles achieve 88-92% cure rates versus only 33-46% with conventional short-term therapy 3
Extended Therapy Considerations
When to Continue Beyond Standard Duration
Long-term methimazole therapy (60-120 months) is highly effective and safe, achieving remission in 83-85% of patients versus 44-47% with conventional duration 4, 5:
- No additional adverse reactions occur after the initial 18-month period, despite continuation for up to 118 additional months 5
- Daily methimazole dose decreases progressively to as low as 2.8-3.5 mg by 24 years of treatment 6
- Suppressed TSH does not occur after 7 years of continuous therapy when properly dosed 6
Predictors of Relapse After Discontinuation
High-risk features for recurrence that favor extended therapy include 4, 5:
- Younger age at diagnosis
- Higher initial triiodothyronine (T3) levels
- Higher TSH receptor antibody concentrations at time of discontinuation
- Lower TSH levels when stopping treatment
- Larger goiter grade
- Specific genetic polymorphisms (rs1879877 CD28, DQB1-05 HLA)
Mandatory Immediate Discontinuation
Life-Threatening Adverse Reactions
Stop methimazole immediately and obtain complete blood count if the patient develops 2, 7:
- Agranulocytosis: Fever or sore throat (potentially life-threatening)
- Leukopenia, thrombocytopenia, or aplastic anemia
- Hepatotoxicity: Anorexia, pruritus, right upper quadrant pain, or transaminases >3 times upper limit of normal 7
- Vasculitis: Including ANCA-positive vasculitis, acute kidney injury, pulmonary hemorrhage, or neuropathy 7
Special Population: Pregnancy
Timing in Pregnant Women
- Switch from methimazole to propylthiouracil when planning pregnancy and during the first trimester due to risk of congenital malformations (aplasia cutis, choanal atresia, esophageal atresia, omphalocele) 7, 1
- If continuing methimazole in pregnancy after first trimester, use the lowest possible dose to maintain FT4/FTI in high-normal range, as the drug crosses the placenta and can cause fetal goiter and cretinism 2, 7
- Many women can discontinue thioamides entirely in the third trimester as Graves' disease often remits spontaneously later in pregnancy 2
- Check TSH every trimester if on levothyroxine replacement after discontinuation 2
Post-Discontinuation Monitoring
Follow-Up Strategy
After stopping methimazole 4, 5:
- Most relapses occur within the first 48 months after withdrawal
- Patients who received long-term therapy (60-120 months) show relapse rates of only 15-19% at 48 months versus 53-56% with conventional duration
- Monitor for recurrence with clinical assessment and thyroid function tests
Alternative to Discontinuation
Definitive Therapy Options
If relapse occurs after completing a course of methimazole, definitive treatment is recommended, though continued long-term low-dose methimazole remains an acceptable alternative 1: